Citius Pharmaceuticals (CTXR)
(Real Time Quote from BATS)
$0.44 USD
-0.03 (-6.00%)
Updated Oct 2, 2024 11:14 AM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CTXR 0.44 -0.03(-6.00%)
Will CTXR be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CTXR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTXR
After Plunging -30.6% in 4 Weeks, Here's Why the Trend Might Reverse for Citius Pharmaceuticals, Inc. (CTXR)
CTXR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CTXR
Biotech Alert: Searches spiking for these stocks today
Citius Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR? (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology
Citius Pharmaceuticals selloff since spinout an opportunity, says EF Hutton
Earnings week ahead: Zoom, Lowe's, Target, Baidu, XPeng, Zim Integrated and more